Get the Stockscreener App
1.465
7.86%
-0.125
Precigen Inc stock is traded at $1.465, with a volume of 1.16M.
It is down -7.86% in the last 24 hours and down -15.32% over the past month.
See More
Previous Close:
$1.59
Open:
$1.55
24h Volume:
1.16M
Relative Volume:
0.60
Market Cap:
$482.23M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-3.7564
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
-19.51%
1M Performance:
-15.32%
6M Performance:
+54.68%
1Y Performance:
+1.03%
1-Day Range:
$1.41
$1.55
1-Week Range:
$1.41
$1.83
52-Week Range:
$0.6513
$2.17
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.465 | 482.23M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.46 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.03 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.78 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.13 | 33.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
270.97 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Insider Monkey
Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald raises Precigen stock target to $5 By Investing.com - Investing.com Australia
10 Hot Biotech Stocks Under $5 - Insider Monkey
Precigen’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Exp - GuruFocus
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch By Investing.com - Investing.com South Africa
Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments - markets.businessinsider.com
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm – PGEN, XON - Business Wire
Stifel maintains Precigen stock Buy rating with $7 target By Investing.com - Investing.com South Africa
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch - Investing.com India
Expert Outlook: Precigen Through The Eyes Of 4 Analysts - Nasdaq
Cantor Fitzgerald raises Precigen stock target to $5 - Investing.com
Stifel maintains Precigen stock Buy rating with $7 target - Investing.com
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target - Investing.com
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises By Investing.com - Investing.com South Africa
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - GuruFocus.com
Precigen earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Precigen Reports Progress and Financial Results for 2024 - TipRanks
Precigen Reports Full Year 2024 Financial Results and Business Updates - The Malaysian Reserve
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises - Investing.com Canada
Precigen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precigen Inc Reports Q4 Net Loss of $(0.47) Per Share, Revenue o - GuruFocus.com
PRECIGEN, INC. SEC 10-K Report - TradingView
How Do Things Look For Precigen Inc (NASDAQ: PGEN) In The Short-Term? - Stocks Register
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - MarketBeat
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - Quantisnow
Precigen Gene Therapy Pioneer Reveals 2024 Performance: Key Financial Results Coming March 19 - StockTitan
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Precigen, Inc. (NASDAQ:PGEN) Stock Holdings Increased by Rhumbline Advisers - Defense World
Precigen (PGEN) Projected to Post Earnings on Tuesday - Defense World
Is Precigen Inc’s (NASDAQ:PGEN) Stock On The Decline? - Stocks Register
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Insider Monkey
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Shares Up 7.7%Time to Buy? - MarketBeat
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (NASDAQ:PGEN) - Seeking Alpha
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha
FDA advances Precigen’s gene therapy for respiratory disease By Investing.com - Investing.com Australia
FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering & Biotechnology News
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com Australia
FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive™
Decades in, this Germantown biopharma is on the cusp of bringing its first product to market - The Business Journals
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
3.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):